Chromadex (NASDAQ:CDXC) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Chromadex (NASDAQ:CDXC) from a sell rating to a hold rating in a research note published on Tuesday morning, reports.

According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “

A number of other research firms have also recently issued reports on CDXC. HC Wainwright set a $7.00 price objective on Chromadex and gave the stock a buy rating in a report on Tuesday, May 28th. BidaskClub cut Chromadex from a buy rating to a hold rating in a report on Friday, May 24th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $6.00.

CDXC opened at $4.25 on Tuesday. The stock has a 50-day moving average price of $4.46 and a 200-day moving average price of $4.15. Chromadex has a 12-month low of $2.79 and a 12-month high of $4.95. The company has a current ratio of 1.55, a quick ratio of 1.11 and a debt-to-equity ratio of 0.09.

Chromadex (NASDAQ:CDXC) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Chromadex had a negative return on equity of 136.15% and a negative net margin of 85.86%. The firm had revenue of $11.10 million during the quarter, compared to analysts’ expectations of $10.81 million. On average, research analysts anticipate that Chromadex will post -0.5 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CDXC. BNP Paribas Arbitrage SA bought a new stake in shares of Chromadex in the 1st quarter valued at about $34,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Chromadex in the 1st quarter valued at about $42,000. Spark Investment Management LLC bought a new stake in shares of Chromadex in the 1st quarter valued at about $78,000. JPMorgan Chase & Co. lifted its stake in shares of Chromadex by 377.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock valued at $208,000 after acquiring an additional 35,418 shares during the last quarter. Finally, Miracle Mile Advisors LLC bought a new stake in shares of Chromadex in the 1st quarter valued at about $272,000. 18.05% of the stock is owned by institutional investors.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Featured Story: What is a CD ladder?

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with's FREE daily email newsletter.